<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01445782</url>
  </required_header>
  <id_info>
    <org_study_id>D3060C00002</org_study_id>
    <secondary_id>Eudract number 2011-002402-75</secondary_id>
    <nct_id>NCT01445782</nct_id>
  </id_info>
  <brief_title>AZD2115 Multiple Ascending Dose Study</brief_title>
  <official_title>A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Inhaled Doses of AZD2115 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This study will investigate the safety and tolerability of AZD2115 following administration
      of multiple ascending doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study
      to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple
      Ascending Inhaled Doses of AZD2115 in Healthy Male Subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Description of the safety profile in terms of adverse events, blood pressure, pulse, temperature, ECG (Electrocardiogram), lung function (Spirometry), physical examination, safety labs</measure>
    <time_frame>baseline, up to 30 days</time_frame>
    <description>No formal statistical tests will be performed. Abnormalities will be listed without statistical analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of the pharmacokinetics (PK) of AZD2115 in terms of area under the curve over the time (AUC) and maximum concentration (Cmax) and terminal half-life</measure>
    <time_frame>day 1</time_frame>
    <description>PK samples collected post-dose at 5mins, 20mins, 40mins, 1hr, 1.5hrs, 2 hrs, 4hrs, 6hrs, 8hrs, 12hrs, 24hrs 36 hrs, 48hrs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of pharmacokinetics (PK) of AZD2115 in terms of Cmax, area under the plasma concentration-time curve from zero to the end of the dosing interval (AUC(0-Ï„))</measure>
    <time_frame>day 17</time_frame>
    <description>PK samples collected post-dose at 5mins, 20mins, 40mins, 1hr, 1.5hrs, 2 hrs, 4hrs, 6hrs, 8hrs, 12hrs, 24hrs 36 hrs, 48hrs 72hrs, 96hrs, 120hrs and 168hrs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of achievement of plasma drug concentration steady state</measure>
    <time_frame>PK samples collected pre-dose on day 1, day 4, day 6, day 10, day 14, day 17</time_frame>
    <description>An exploratory analysis of achievement of steady state will be evaluated graphically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of pharmacodynamics of AZD2115 in terms of FEV1 (forced expiratory volume in the first second), FVC (forced vital capacity), potassium, glucose, systolic and diastolic blood pressure, pulse rate, heart rate, QTcF</measure>
    <time_frame>day 1, day 17</time_frame>
    <description>QTcF defined as QT interval corrected for heart rate using Fridericia's formula</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD2115</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to AZD2115</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2115</intervention_name>
    <description>Multiple dose, oral inhalation (nebuliser solution)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Multiple dose, oral inhalation (nebuliser solution)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects aged 18 to 45 years with suitable veins for cannulation or
             repeated venepuncture

          -  Male subjects should be willing to use barrier contraception ie, condoms and
             spermicide, from the day of first administration of the AZD2115 until 3 months after
             administration and must not donate sperm for 3 months after follow-up

          -  Have a body mass index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no
             more than 100 kg

        Exclusion Criteria:

          -  Abnormal vital signs, after 10 minutes supine rest, defined as any of the following:

               -  Systolic BP &gt;140 mmHg

               -  Diastolic BP &gt;90 mmHg

               -  Heart rate &lt;40 or &gt;85 bpm

          -  Prolonged QTcF &gt;450 ms or shortened QTcF &lt;340 ms or family history of long QT syndrome

          -  Serum potassium concentration of &lt; 3.80 mmol/L on admission (Day -1)

          -  History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as
             judged by the investigator or history of hypersensitivity to drugs with the same class
             to AZD2115 or to excipients

          -  History or presence of gastrointestinal, pulmonary, hepatic or renal disease or any
             other condition known to interfere with absorption, distribution, metabolism or
             excretion of drugs
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2011</study_first_submitted>
  <study_first_submitted_qc>October 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2011</study_first_posted>
  <last_update_submitted>October 5, 2012</last_update_submitted>
  <last_update_submitted_qc>October 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>healthy</keyword>
  <keyword>inhaled</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

